Zydus Hydrocortisone Sodium Succinate for Injection
Hydrocortisone Sodium Succinate for Injection failed impurities and degradation specifications.
Hydrocortisone Sodium Succinate for Injection failed impurities and degradation specifications.
Tretinoin Cream USP, 0.05% failed impurities and degradation specifications.
3 productsFosfomycin Tromethamine Granules for Oral Solution failed impurities and degradation specifications.
Olanzapine Tablets, USP 5 mg, failed impurities and degradation specifications.
Phytonadione Injectable Emulsion failed impurities and degradation specifications.
Fluphenazine Hydrochloride Tablets failed impurity specifications during stability testing.
Ramipril Capsules USP, 10 mg, failed impurity specifications.
Mirabegron Extended-Release Tablets contain an impurity above specification.
Dabigatran Etexilate Capsules failed impurity and degradation specifications.
4 productsGlycopyrrolate Oral Solution failed impurities and degradation specifications due to an unidentified impurity.
3 productsDabigatran etexilate capsules failed impurity and degradation specifications during stability testing.
2 productsFexofenadine Hydrochloride Tablets failed impurities and degradation specifications.
Methohexital Sodium failed impurities and degradation specifications.
Methohexital Sodium for Injection failed impurities and degradation specifications.
CGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
3 productsDuloxetine D/R contains an impurity above the FDA recommended interim limit.
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Duloxetine Delayed-Release Capsules contain an impurity above the FDA recommended interim limit.
2 productsEpinephrine Injection failed impurities and degradations specifications.
Duloxetine DR Capsules contain a nitrosamine impurity above the acceptable limit.
The patch failed impurity tests due to elevated oxidative-related impurities.
Reason given by FDA: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit.
2 productsBusulfan Injection failed impurities and degradation specifications.
Duloxetine Delayed-Release Capsules contain an impurity above the recommended limit.
Enalapril Maleate Tablets failed impurities/degradation specifications due to an out-of-specification result in organic impurities test.
Duloxetine Delayed-Release Capsules contain an impurity above the FDA recommended limit.
3 productsCGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Claravis (isotretinoin capsule, USP), 10 mg, failed impurities/degradation specifications for specific impurity Tretinoin.
3 productsReason given by FDA: CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit.
3 productsPrazosin Hydrochloride Capsules contain a nitrosamine impurity above acceptable limits.
3 productsBromfenac Ophthalmic Solution 0.07% failed impurities and degradation specifications at the 20th month stability testing.
TraMADol Hydrochloride Tablets contain an impurity that failed specifications.
Dexamethasone Sodium Phosphate Injection failed impurity specifications.
Temozolomide Capsules failed impurities and degradation specifications during stability testing.
Bisoprolol Fumarate and Hydrochlorothiazide tablets fail to meet impurity specification limits.